Martin Fromm

Martin Fromm is a Professor of Clinical Pharmacology and Toxicology at Friedrich-Alexander University Erlangen-Nürnberg, where he has served as Director of the Institute of Experimental and Clinical Pharmacology and Toxicology since 2004. His career includes prior roles as Acting Professor (2002–2004), Group Leader (1999–2002), and postdoctoral fellowships at the Dr. Margarete-Fischer-Bosch Institute (1992–1996) and Vanderbilt University (1997–1999).

• Research Focus: Mechanisms of variable drug effects, drug transporters, medication safety, and biomarker development for transporter-mediated drug interactions.
• Publications: Over 170 original articles and 49 reviews with an h-index of 76 (24,000+ citations).
• Leadership: Chair of the University Hospital Erlangen's drug utilization committee and steering board of the Center of Clinical Studies.

Scientific Awards:

• Top 3% Highly Cited Researcher (AD Scientific Index 2022–2024)
• Top 2% Highly Cited Researcher (Stanford List 2023)
• MSD Health Award (2021)
• Paul-Martini-Award (2001)
• Presidential Trainee Award (1998)

Research Trends: His recent work integrates metabolomics, machine learning (LC-MS methods), and clinical studies to enhance medication safety in oncology and geriatrics. Earlier studies focus on transporter proteins (e.g., OCT2, MATE1, P-glycoprotein) and their role in drug absorption, metabolism, and interactions.

Grants & Collaborations: Funded by DFG, BMBF, BMG, and Deutsche Krebshilfe. Active in ethics committees and clinical pharmacology societies.